Bristol Myers Squibb stock trades below its 52-week high

Published on 09/25/2026 at 11:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bristol Myers Squibb stock posted USD 12.97 billion in second quarter revenue, up 5.7 percent year over year. Adjusted EPS reached USD 2.04 against USD 1.60 consensus.

BMY, US1101221083, Illustration mit AI erstellt.

Bristol Myers Squibb (ISIN US1101221083) stood at USD 61.50 on the NYSE on September 24, 2026, 10.4 percent below its 52-week high of USD 68.64. The next scheduled reporting date is October 29, 2026, when the company is set to publish third quarter 2026 results.

Second quarter beat expectations

The latest operating data provide the strongest company-specific reference point. For the second quarter of 2026, Bristol Myers Squibb reported revenue of USD 12.97 billion, up 5.7 percent from the prior-year quarter, according to MarketBeat in its September 2026 report.

Adjusted earnings per share reached USD 2.04 for the quarter, exceeding the USD 1.60 consensus estimate by USD 0.44. The revenue comparison was also positive, with reported sales of USD 12.97 billion versus the USD 11.74 billion analyst estimate, according to MarketBeat.

Guidance sets the next test

Bristol Myers Squibb maintained fiscal 2026 adjusted EPS guidance of USD 6.75-7.00, the same MarketBeat report said. That range gives investors a defined benchmark for the October results, particularly after the second quarter beat consensus by USD 0.44 per share.

The market snapshot adds a valuation and risk frame. The share price was USD 19.00 above the 52-week low of USD 42.52, while market capitalization stood at USD 125.63 billion and trading volume reached 14.18 million shares on September 24, 2026.

October date anchors the stock

Bristol Myers Squibb will announce third quarter 2026 results on October 29, 2026, according to Yahoo Finance, which carried the company announcement dated September 18, 2026. The upcoming report will put the USD 6.75-7.00 full-year adjusted EPS range alongside fresh quarterly performance.

Bristol Myers Squibb stock therefore combines a measurable earnings comparison with a clearly defined reporting checkpoint. Its September 24 price of USD 61.50 was accompanied by a daily gain of 0.57 percent, with the 52-week high remaining USD 7.14 higher.